bioRxiv Science⌕ Search

Biology subjects

Kaufmann, M. M.

Publications and source records attributed to Kaufmann, M. M..

3 recordsLinked to original sources

CRISCross: Integration of Epigenetic Information for Deep-Learning-Based Prediction of CRISPR-Cas9 Off-Targets Across Cell Types

CRISPR-Cas9 enables precise genome editing but remains limited by off-target effects, raising safety concerns and necessitating accurate prediction. Although epigenetic features influence Cas9 binding and cleavage, their predictive signals are often weak, highlyvariable, and context-dependent, limiting the effectiveness of existing machine learning approaches. Cross-cell-type settings are especially challenging: epigenetic landscapes differ substantially, and models trained on one cell type frequently fail to generalize. Here, we systematically investigate the role of epigenetic context in off-target prediction and demonstrate that its utility depends on modeling interactions with sequence features rather than treating it as an independent signal. Tabular and deep learning experiments demonstrate that epigenetic features provide a consistent but modestly complementary signal, and that late-stage fusion strategies are insufficient to effectively exploit this information. To address this, we introduce CRISCross, a cross-attention-based architecture that captures sequence-epigenetic interactions at the nucleotide level, alongside CRISPRAT, a synthetic pretraining strategy that learns transferable representations from genome-derived sgRNA-off-target pairs without relying on dataset-specific pretraining. CRISCross, incorporating AlphaGenome-derived chromatin accessibility signals, shows better predictive performance than sequence-only baselines across three independent test datasets spanning two cell types, demonstrating improved generalization across guide RNAs, datasets, and cellular contexts. This is particularly relevant for therapeutic applications involving cell types or patient-derived contexts that lack dedicated experimental datasets. In such settings, predicted chromatin accessibility may provide scalable contextual information when direct epigenomic profiling is unavailable or impractical. Together, these results show that accurate CRISPR off-target prediction benefits from interaction-aware integration of epigenetic context alongside generalizable pretraining strategies.

bioinformatics↗

Clinical development of gene edited tacrolimus-resistant Treg (FKBP12KO-Treg) to enable simultaneous immunosuppression and support of immune regulation

Background: Unwanted immune responses play a central role in the pathogenesis of solid organ allograft rejection. These are managed by life-long immunosuppression with considerable burden for the patient and society. Adoptive therapy with regulatory T-cells (Treg) is a promising approach to restore sustainable immune balance and avoid long-term adverse effects of immunosuppression. While Treg effectively inhibit activation of unwanted immune responses, they are less effective in controlling pre-existing/activated memory effector T-cells (Teff). Thus, co-administration of Treg with immunosuppressants is required to achieve a sustainable organ acceptance. Calcineurin inhibitors (CNI) are powerful in controlling de novo generated and preformed Teff. However, CNI also dampen Treg immunoregulatory function. Thus, we hypothesize improved results of adoptive Treg therapy in immunosuppressed patients applying tacrolimus-resistant Treg. Methods: While retaining CNI modulation of Teff with tacrolimus, we knocked-out FKBP12 in Treg (FKBP12KO-Treg) by gene-editing using ribonucleoprotein-based CRISPR/Cas9 technology to generate tacrolimus-resistant Treg and characterised them using flow cytometry, functional assays and in-depth phenotyping. Results: This detailed in vitro analysis showed FKBP12KO-Treg were comparable to non-gene edited Treg and impervious to tacrolimus while maintaining immunoregulatory function and sensitivity to alternative CNIs raising no safety concerns. Furthermore, we aligned our methodology to achieve GMP compliance laying the basis for a manufacturing license in preparation of a clinical trial. Conclusion: Based on the presented preclinical dataset implying safety and efficacy of FKBP12KO-Treg, we are now seeking to undertake a proof-of-concept clinical trial to evaluate the co-administrationof FKBP12KO-Treg and tacrolimus to enhance the management of living donor kidney transplant recipients.

immunology↗

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development

The identification of HIV-1 Envelope glycoprotein (Env) traits associated with development of neutralization cross-reactivity in natural infection is critical for vaccine design. Here we describe the presence of additional Cysteine (Cys) residues in V1 that are enriched among people with elite neutralization breadth. Using >65,000 V1 sequences from the CATNAP database, the AMP trials and three large longitudinal HIV infection cohorts, the SHCS, ZPHI and CAPRISA studies, we show that Env variants with extra V1 Cys are present at low levels throughout infection and fluctuate in frequency over time within participants. We demonstrate an independent association of extra V1 Cys with elite plasma neutralization, and a strong preference for two versus one extra Cys, suggesting certain Envs introduce an additional disulfide bond for stabilization. We observed high levels of neutralization resistance among Envs from 34 bNAb donors, of which 17.6% had elongated V1 regions with extra Cys. We show that extra V1 Cys moderately increase neutralization resistance in an Env from a V2- Apex bNAb-inducer. Modulation of the accessibility of bNAb epitopes on this Env by extra V1 Cys enhanced epitope shielding of several regions, but increased V2 exposure. This suggests that escape from autologous neutralizing activity drove insertion of the extra V1 Cys, creating a modified antigen that may have favored V2 bNAb induction in this donor. Overall, we identify a rare motif of twin Cys in V1 that confers increased neutralization resistance and Env stabilization, is associated with bNAb induction, and may hold potential for incorporation into future HIV bNAb immunogens.

immunology↗